Michel Eichelbaum

33.5k total citations · 5 hit papers
335 papers, 25.4k citations indexed

About

Michel Eichelbaum is a scholar working on Pharmacology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michel Eichelbaum has authored 335 papers receiving a total of 25.4k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Pharmacology, 128 papers in Oncology and 84 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michel Eichelbaum's work include Pharmacogenetics and Drug Metabolism (157 papers), Drug Transport and Resistance Mechanisms (105 papers) and Pharmacological Effects and Toxicity Studies (65 papers). Michel Eichelbaum is often cited by papers focused on Pharmacogenetics and Drug Metabolism (157 papers), Drug Transport and Resistance Mechanisms (105 papers) and Pharmacological Effects and Toxicity Studies (65 papers). Michel Eichelbaum collaborates with scholars based in Germany, United States and Switzerland. Michel Eichelbaum's co-authors include Ulrich M. Zanger, Matthias Schwab, Oliver Burk, Martin F. Fromm, Ulrich Brinkmann, Oliver von Richter, Elke Schaeffeler, Sebastian Raimundo, Anke Geick and Kathrin Klein and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michel Eichelbaum

330 papers receiving 24.4k citations

Hit Papers

Functional polymorphisms of the human multidrug... 1979 2026 1994 2010 2000 1999 2001 2004 1979 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    2000 2.0k citations Oliver Burk, Michel Eichelbaum et al. profile →
  2. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    1999 734 citations Bernd Greiner, Michel Eichelbaum et al. profile →
  3. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
    2001 702 citations Michel Eichelbaum, Oliver Burk et al. profile →
  4. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
    2004 623 citations Ulrich M. Zanger, Michel Eichelbaum et al. profile →
  5. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
    1979 474 citations Michel Eichelbaum et al. European Journal of Clinical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Eichelbaum Germany 87 12.0k 11.4k 6.8k 4.7k 2.6k 335 25.4k
Kenneth E. Thummel United States 73 11.5k 1.0× 7.2k 0.6× 4.7k 0.7× 3.1k 0.7× 1.8k 0.7× 263 20.2k
Ulrich M. Zanger Germany 74 10.1k 0.8× 6.8k 0.6× 3.1k 0.5× 5.1k 1.1× 1.7k 0.6× 197 19.8k
Erin G. Schuetz United States 77 9.8k 0.8× 9.7k 0.8× 4.0k 0.6× 4.7k 1.0× 1.1k 0.4× 198 19.9k
Magnus Ingelman‐Sundberg Sweden 96 18.2k 1.5× 7.8k 0.7× 3.0k 0.4× 10.8k 2.3× 3.1k 1.2× 527 35.5k
Leslie Z. Benet United States 80 8.4k 0.7× 9.5k 0.8× 6.1k 0.9× 5.0k 1.1× 3.8k 1.5× 510 26.5k
Pertti J. Neuvonen Finland 84 10.9k 0.9× 8.1k 0.7× 5.7k 0.8× 3.1k 0.7× 4.1k 1.5× 506 26.6k
Ivar Roots Germany 68 5.9k 0.5× 4.9k 0.4× 3.3k 0.5× 4.7k 1.0× 1.8k 0.7× 253 16.4k
Richard B. Kim Canada 74 5.7k 0.5× 9.1k 0.8× 4.7k 0.7× 3.7k 0.8× 1.5k 0.6× 243 18.5k
Paul B. Watkins United States 73 11.5k 1.0× 6.2k 0.5× 3.2k 0.5× 3.5k 0.7× 2.2k 0.8× 246 19.9k
Steven Wrighton United States 71 11.1k 0.9× 6.7k 0.6× 2.6k 0.4× 3.9k 0.8× 1.8k 0.7× 172 17.1k

Countries citing papers authored by Michel Eichelbaum

Since Specialization
Citations

This map shows the geographic impact of Michel Eichelbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Eichelbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Eichelbaum more than expected).

Fields of papers citing papers by Michel Eichelbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Eichelbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Eichelbaum. The network helps show where Michel Eichelbaum may publish in the future.

Co-authorship network of co-authors of Michel Eichelbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Eichelbaum. A scholar is included among the top collaborators of Michel Eichelbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Eichelbaum. Michel Eichelbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schroth, Werner, Ute Hamann, Peter A. Fasching, et al.. (2010). CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification. Clinical Cancer Research. 16(17). 4468–4477. 66 indexed citations
2.
Ji, Yuan, Janet E. Olson, Jianping Zhang, et al.. (2008). Breast Cancer Risk Reduction and Membrane-Bound Catechol O -Methyltransferase Genetic Polymorphisms. Cancer Research. 68(14). 5997–6005. 36 indexed citations
3.
Schroth, Werner, Péter Fritz, Matthias Schwab, et al.. (2007). Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. Journal of Clinical Oncology. 25(33). 5187–5193. 336 indexed citations
4.
Gradhand, Ulrike, Heike Tegude, Oliver Burk, et al.. (2007). Functional analysis of the polymorphism −211C>T in the regulatory region of the human ABCC3 gene. Life Sciences. 80(16). 1490–1494. 20 indexed citations
5.
Lang, Thomas, Monika Hitzl, Oliver Burk, et al.. (2004). Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics. 14(3). 155–164. 81 indexed citations
6.
Glaeser, Hartmut, Siegfried Drescher, Michel Eichelbaum, & Martin F. Fromm. (2004). Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. British Journal of Clinical Pharmacology. 59(2). 199–206. 62 indexed citations
7.
Coller, Janet K., Kathrin Klein, Renzo Wolbold, et al.. (2003). Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology. 57(1). 105–111. 23 indexed citations
8.
Fischer, Joachim E., Matthias Schwab, Michel Eichelbaum, & Ulrich M. Zanger. (2003). Mutational Analysis of the Human Dihydropyrimidine Dehydrogenase Gene by Denaturing High-Performance Liquid Chromatography. Genetic Testing. 7(2). 97–105. 16 indexed citations
9.
Greiner, Bernd, Martin F. Fromm, R. Fraser, et al.. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology & Therapeutics. 70(3). 217–227. 69 indexed citations
10.
Glaeser, Hartmut, Siegfried Drescher, Oliver Burk, et al.. (2001). Induction of CYP2C8, CYP2C9, and CYP3A4 by rifampin in shedded human enterocytes.. Drug Metabolism Reviews. 33. 90. 1 indexed citations
11.
Fromm, Martin F., Hans-Martin Kauffmann, Péter Fritz, et al.. (2000). The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters. American Journal Of Pathology. 157(5). 1575–1580. 208 indexed citations
12.
Fromm, Martin F., Dagmar Busse, H. Kroemer, & Michel Eichelbaum. (1996). Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin. Hepatology. 24(4). 796–801. 214 indexed citations
13.
Eichelbaum, Michel, et al.. (1993). Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines. Cancer Chemotherapy and Pharmacology. 32(2). 151–155. 5 indexed citations
14.
Ebner, Thomas & Michel Eichelbaum. (1993). The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.. British Journal of Clinical Pharmacology. 35(4). 426–430. 19 indexed citations
15.
Eichelbaum, Michel. (1992). Enantiomers: Implications andComplications in DevelopmentalPharmacology. Developmental Pharmacology and Therapeutics. 18(3-4). 131–134. 11 indexed citations
16.
Gaedigk, Andrea, Martin Blum, Roger Gaedigk, Michel Eichelbaum, & Urs Meyer. (1991). Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.. PubMed. 48(5). 943–50. 219 indexed citations
17.
Turgeon, Jacques, Céline Fiset, Robert Giguère, et al.. (1991). Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.. Journal of Pharmacology and Experimental Therapeutics. 259(2). 789–798. 53 indexed citations
18.
Mikus, Gerd, Michel Eichelbaum, Christine Fischer, et al.. (1990). Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action.. Journal of Pharmacology and Experimental Therapeutics. 253(3). 1042–1048. 57 indexed citations
19.
Eichelbaum, Michel & N. M. Woolhouse. (1985). Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. European Journal of Clinical Pharmacology. 28(1). 79–83. 37 indexed citations
20.
Bertilsson, Leif, Michel Eichelbaum, Britt Mellström, Juliette Säwe, & Folke Sjöqvist. (1982). Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes. British Journal of Clinical Pharmacology. 14(4). 602. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth E. Thummel Breakdown of academic impact, for papers by Ulrich M. Zanger Breakdown of academic impact, for papers by Erin G. Schuetz Breakdown of academic impact, for papers by Magnus Ingelman‐Sundberg Breakdown of academic impact, for papers by Leslie Z. Benet Breakdown of academic impact, for papers by Pertti J. Neuvonen Breakdown of academic impact, for papers by Ivar Roots Breakdown of academic impact, for papers by Richard B. Kim Breakdown of academic impact, for papers by Paul B. Watkins Breakdown of academic impact, for papers by Steven Wrighton
Rankless by CCL
2026